Clinical Trials
38 trialsOTT 15-05
Ottawa Hospital Research Institute
HIMALAYAS-P
University Health Network, Toronto
ATOPE
Universidad de Granada
CCTGuide Pilot
Abramson Cancer Center at Penn Medicine
DAPA-AIC
Hawler Medical University
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
NTproBNP-Guide
Abramson Cancer Center at Penn Medicine
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
University of Virginia
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
University of Sao Paulo General Hospital
CARMA
Cedars-Sinai Medical Center
Cardiac Effects From Radiation Therapy by MRI
University of Colorado, Denver
CATCH
Vejle Hospital
Cardiotoxicity Monitoring With Single-lead Electrocardiogram
I.M. Sechenov First Moscow State Medical University
ECHOS2
Washington University School of Medicine
BACCARAT
Institut de Radioprotection et de Surete Nucleaire
BRAVEHeart
University of Sydney
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
Wake Forest University Health Sciences
ONCORE
Hospital Clinico Universitario de Santiago
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Children's Cancer Hospital Egypt 57357
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Remote Ischaemic Preconditioning in Childhood Cancer
The University of Hong Kong
ANKE
Heinrich-Heine University, Duesseldorf
CA2D
University Hospital, Bordeaux
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
University of South Florida
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
Horus University
Acute Exercise Cardioprotection From Doxorubicin
University of British Columbia
HF-PROACTIVE
Henry Ford Health System
Ceccy
University of Sao Paulo
MYOTAX
Catharina Ziekenhuis Eindhoven
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
The Netherlands Cancer Institute
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Fudan University
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
Children's Oncology Group
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
Children's Oncology Group
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
Children's Oncology Group
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Children's Oncology Group
Doxo
University Hospital Muenster
T-Cell #4
Children's Oncology Group
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)